Punicalagin attenuated cerebral ischemia–reperfusion insult via inhibition of proinflammatory cytokines, up-regulation of Bcl-2, down-regulation of Bax, and caspase-3

详细信息    查看全文

• 作者：Lavanya Yaidikar ; Santhrani Thakur
• 关键词：Cerebral ischemia–reperfusion injury ; Punicalagin ; Neuroprotection ; Anti ; inflammatory action ; Anti ; apoptotic activity
• 刊名：Molecular and Cellular Biochemistry
• 出版年：2015
• 出版时间：April 2015
• 年：2015
• 卷：402
• 期：1-2
• 页码：141-148
• 全文大小：547 KB
• 参考文献：1. Elkind MS (2009) Outcomes after stroke: risk of recurrent ischemic stroke and other events. Am J Med 122(4):S7–S13 CrossRef
  2. Park CK, Nehls DG, Graham DI, Teasdale GM, McCulloch J (1988) The glutamate antagonist MK-801 reduces focal ischemic brain damage in the rat. Ann Neurol 24(4):543-51 CrossRef
  3. Nakamura T, Minamisawa H, Katayama Y, Ueda M, Terashi A, Nakamura K, Kudo Y (1999) Increased intracellular Ca²⁺ concentration in the hippocampal CA1 area during global ischemia and reperfusion in the rat: a possible cause of delayed neuronal death. Neuroscience 88(1):57-7 CrossRef
  4. Peters O, Back T, Lindauer U, Busch C, Megow D, Dreier J, Dirnagl U (1998) Increased formation of reactive oxygen species after permanent and reversible middle cerebral artery occlusion in the rat. J Cereb Blood Flow Metab 18(2):196-05 CrossRef
  5. Lakhan SE, Kirchgessner A, Hofer M (2009) Inflammatory mechanisms in ischemic stroke: therapeutic approaches. J Transl Med 7:97 CrossRef
  6. Nakka VP, Gusain A, Mehta SL, Raghubir R (2008) Molecular mechanisms of apoptosis in cerebral ischemia: multiple neuroprotective opportunities. Mol Neurobiol 37(1):7-8 CrossRef
  7. Mehta SL, Manhas N, Raghubir R (2007) Molecular targets in cerebral ischemia for developing novel therapeutics. Brain Res Rev 54(1):34-6 CrossRef
  8. Szewka AJ, Prabhakaran S (2009) An update on acute ischemic stroke therapies. Compr Ther 35(2):72-0
  9. Zhou XQ, Zeng XN, Kong H, Sun XL (2008) Neuroprotective effects of berberine on stroke models in vitro and in vivo. Neurosci Lett 447(1):31-6 CrossRef
  10. Ning N, Dang X, Bai C, Zhang C, Wang K (2012) Panax notoginsenoside produces neuroprotective effects in rat model of acute spinal cord ischemia–reperfusion injury. J Ethnopharmacol 139(2):504-12 CrossRef
  11. Ahmed MAE, El-Morsy EM, Ahmed AAE (2014) Pomegranate extract protects against cerebral ischemia/reperfusion injury and preserves brain DNA integrity in rats. Life Sci 110(2):61-9 CrossRef
  12. Tyagi S, Singh A, Bharadwaj P, Sahu S, Yadav AP, Kori ML (2012) Punicalagins—a large polyphenol compounds found in pomegranates: a therapeutic review. Acad J Plant Sci 5(2):45-9
  13. Yaidikar L, Thakur SR (2014) Neuroprotective effect of Punicalagin against cerebral ischemia reperfusion induces oxidative brain injury. J Stroke Cerebrovasc Dis 23(10):2869-878. doi:10.1016/j.jstrokecerebrovasdis.2014.07.020 CrossRef
  14. Longa EZ, Weinstein PR, Carlson S, Cummins R (1989) Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke 20:84-1 CrossRef
  15. Moran PM, Higgins LS, Cordel B, Moser PC (1995) Age related learning deficits in transgenic mice expressing 721 amino acid Isoforms of human beta amyloid precursor protein. Proc Natl Acad Sci USA 92(12):5341-345 CrossRef
  16. Schallert T, Upchurch M, Lobaugh N, Farrar SB, Spirduso WW, Gilliam P, Vaughn D, Wilcox RE (1982) Tactile extinction, distinguishing between sensorimotor and motor asymmetries in rats with unilateral nigrostriatal damage. Pharmacol Biochem Behav 16(3):455-62 CrossRef
  17. Bouet V, Feret T, Toutain J, Divoux D, Boulouard M, Schum
• 刊物类别：Biomedical and Life Sciences
• 刊物主题：Life Sciences
  Biochemistry
  Medical Biochemistry
  Oncology
  Cardiology
  
• 出版者：Springer Netherlands
• ISSN：1573-4919

文摘

Punicalagin (PG) is a hydrolysable tannin compound found in Punica granatum L. The purpose of the present work is to explore the neuroprotective mechanism of PG against ischemia–reperfusion (I/R) injury in rat model of middle cerebral artery occlusion (MCAO). Rats were randomly divided into sham, MCAO, and PG-treated groups. PG (15 and 30?mg/kg), the vehicle was administered orally for 7?days prior to MCAO. Rats were anesthetised with ketamine (100?mg/kg/im), xylazine (10?mg/kg/im) and subjected to 2?h occlusion and 22?h reperfusion. The effects of PG on behavioral deficit and infarct volume, the levels of glutamate and calcium as well as the levels of inflammatory cytokines tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), interleukin-6 (IL-6) were evaluated. Moreover, the expressions of caspase-3, Bcl-2, and Bax were detected by Western blotting. As compared with MCAO group, PG-treated rats showed dose-dependent reduction in infarct volume and substantial improvement in behavioral deficit. The levels of glutamate, calcium, TNF-α, IL-1β, and IL-6 were restored significantly. The Western blotting results revealed that the expression of Bcl-2 was up-regulated and that of caspase-3, Bax were down-regulated when exposed to PG. From our results, it can be concluded that PG showed an ameliorative effect against cerebral I/R injury in rats through its anti-inflammatory, antioxidant actions besides it inhibits excitotoxicity. It also suppresses apoptosis through regulating, Bcl-2, caspase-3, and Bax protein expressions, perhaps another mechanism by which PG employs its neuroprotective action.